iCare, a subsidiary of Revenio Group, has today announced updates on the release of the new version of the iCare MAIA® microperimeter.

The new iCare MAIA® microperimeter which retains all the key features that made it the gold standard in microperimetry, is currently in the final stages of preparation. We are pleased to confirm that the commercial launch of the new version is scheduled for the first quarter of next year. This update represents a significant step in our growth and innovation strategy, aimed at better meeting market diagnostic needs, particularly within the ophthalmic research segment focusing on geographic atrophy therapies development.

The new iCare MAIA® has a renewed hardware platform with fully automated operations and a 15’’ multi-touch display, making it easier than ever. The auto-alignment capability is especially useful as it keeps the device aligned with the eye under exam, compensating for head movements throughout the test. The unparalleled structure-function correlation is now improved thanks to the introduction of the 60° TrueColor field of view.

“iCare MAIA® retains all the key elements that made it the gold standard in microperimetry technology, the introduction of the 60° TrueColor imaging capabilities brings the new MAIA® to the next level of structure-function correlation in microperimetry” said Daniele Mantovano, iCare’s GlobalBusiness Line Director. “We strongly believe in microperimetry and its usefulness in the research ophthalmic segment, and we have been intensely working on this project since the discontinuation of the previous MAIA® model”.

Clinical validation indicates full interchangeability with previous MAIA® generation with equivalent sensitivity results in mesopic testing.

The new iCare MAIA® has a 15’’ multi-touch display and an intuitive User Interface allowing easy-to-follow operations. The onboard grid editor allows to create customized test patterns, ensuring higher flexibility for the execution of custom protocols for patient-specific testing. The new iCare MAIA® can import data from the previous model and use it as a reference for follow-up examination guaranteeing full continuity with clinical historical data.

Read more at www.icare-world.com/product/icare-maia-microperimetry-system/

For further information, please contact
Daniele Mantovano, Global Business Line Diagnostics Director
tel. +39 346 100 8040
daniele.mantovano@icare-world.com

Distribution
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

iCare in brief
iCare is a Finnish company that develops and manufactures innovative hand-held tonometers, fundus imaging devices, perimeters and software solutions for the diagnosis and screening of eye diseases. iCare's vision is to keep the world visible to everyone, and its goal is to facilitate the identification and treatment of eye diseases through its technological solutions. iCare's products are reliable, efficient, and user-friendly, enabling accurate diagnoses to be made at an early stage. iCare collaborates with industry experts and is committed to continually developing new solutions to promote eye health. iCare is part of Helsinki Stock Exchange listed Revenio Group Corporation. www.icare-world.com